Surface Oncology, Inc. (SURF): Price and Financial Metrics
SURF Price/Volume Stats
| Current price | $1.07 | 52-week high | $1.43 |
| Prev. close | $1.08 | 52-week low | $0.56 |
| Day low | $1.01 | Volume | 1,510,100 |
| Day high | $1.09 | Avg. volume | 430,375 |
| 50-day MA | $0.96 | Dividend yield | N/A |
| 200-day MA | $0.82 | Market Cap | 65.08M |
SURF Stock Price Chart Interactive Chart >
Surface Oncology, Inc. (SURF) Company Bio
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.
Latest SURF News From Around the Web
Below are the latest news stories about SURFACE ONCOLOGY INC that investors may wish to consider to help them evaluate SURF as an investment opportunity.
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40MCoherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O pipeline: SRF388, currently in Phase 2 trials in lung and liver cancer, and SFR114, currently in a Phase 1/2 study as a monotherapy for advanced solid tumors. Coherus will issue shares at $5.2831 per s |
Coherus to Acquire Surface Oncology– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 million at closing; Surface shareholders will also |
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fir |
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research ( |
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the p |
SURF Price Returns
| 1-mo | -0.93% |
| 3-mo | 19.25% |
| 6-mo | 65.76% |
| 1-year | 2.88% |
| 3-year | -84.71% |
| 5-year | -89.01% |
| YTD | 30.49% |
| 2022 | -82.85% |
| 2021 | -48.27% |
| 2020 | 391.49% |
| 2019 | -55.66% |
| 2018 | N/A |
Continue Researching SURF
Want to do more research on Surface Oncology Inc's stock and its price? Try the links below:Surface Oncology Inc (SURF) Stock Price | Nasdaq
Surface Oncology Inc (SURF) Stock Quote, History and News - Yahoo Finance
Surface Oncology Inc (SURF) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...